Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Oxford BioDynamics chair on key collaboration with Google Cloud
MP3•Episode home
Manage episode 501738231 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) executive chairman Iain Ross talked with Proactive's Stephen Gunnion about the company’s new partnership with Google Cloud, a move he described as a major growth catalyst for both Oxford BioDynamics and the field of 3D genomics. Ross outlined how the deal will support the global scaling of the company’s EpiSwitch platform by making it cloud native, allowing faster deployment, greater accessibility, and continuous updates. “This deal will accelerate the adoption of our 3D genomics platform. It’ll expand into different markets and it will build recurring revenues,” he said. By leveraging Google’s cloud, AI, and machine learning infrastructure, Oxford BioDynamics aims to streamline data processing and reach new partners in the pharmaceutical and biotech industries. Ross highlighted that the partnership boosts credibility by aligning OBD with Google and its other life sciences initiatives like DeepMind and AlphaFold. The company expects in due course to benefit from new revenue streams through licensing, access fees, and one-off purchases. Ross said the cloud transition enables wider use of the platform and access to broader diagnostics and clinical markets. He noted that the addressable market for genomics could reach $175 billion within the next decade. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe, and turn on notifications for future content. #OxfordBioDynamics #GoogleCloud #3DGenomics #EpiSwitch #PrecisionMedicine #BiotechNews #GenomicsInnovation #CloudComputing #HealthcareAI #PharmaTech #LifeSciences #MolecularDiagnostics
…
continue reading
605 episodes
MP3•Episode home
Manage episode 501738231 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) executive chairman Iain Ross talked with Proactive's Stephen Gunnion about the company’s new partnership with Google Cloud, a move he described as a major growth catalyst for both Oxford BioDynamics and the field of 3D genomics. Ross outlined how the deal will support the global scaling of the company’s EpiSwitch platform by making it cloud native, allowing faster deployment, greater accessibility, and continuous updates. “This deal will accelerate the adoption of our 3D genomics platform. It’ll expand into different markets and it will build recurring revenues,” he said. By leveraging Google’s cloud, AI, and machine learning infrastructure, Oxford BioDynamics aims to streamline data processing and reach new partners in the pharmaceutical and biotech industries. Ross highlighted that the partnership boosts credibility by aligning OBD with Google and its other life sciences initiatives like DeepMind and AlphaFold. The company expects in due course to benefit from new revenue streams through licensing, access fees, and one-off purchases. Ross said the cloud transition enables wider use of the platform and access to broader diagnostics and clinical markets. He noted that the addressable market for genomics could reach $175 billion within the next decade. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe, and turn on notifications for future content. #OxfordBioDynamics #GoogleCloud #3DGenomics #EpiSwitch #PrecisionMedicine #BiotechNews #GenomicsInnovation #CloudComputing #HealthcareAI #PharmaTech #LifeSciences #MolecularDiagnostics
…
continue reading
605 episodes
Tous les épisodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.